{
  "docId": "019de076-b8a1-76db-a88b-3941d3b29d31",
  "docSlug": "785649d6ad3bf1f87bd264132bed44c1",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 25,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b8a1-76db-a88b-3941d3b29d31/15",
  "deckHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31",
  "deckJsonHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31.json",
  "deckAnchorHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.95,
        "x": 0.03,
        "y": 0.415
      },
      "kind": "list",
      "text": "Differentiated Features: Highly selective; Unique mechanism of action - Complete shut-down of the SRC pathway by scaffold and catalytic domain inactivation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "091fbad5-147f-4727-bbc2-823f5ba444ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.95,
        "x": 0.03,
        "y": 0.592
      },
      "kind": "list",
      "text": "Strong Preclinical Proof of Concept: POC in multiple xenograft models – significant single-agent activity in squamous cell cancer models; Ability to re-sensitize resistant NSCLC cells to osimertinib; Ability to reverse resistance to enzalutamide in vivo in mCRPC",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bcd80a71-fd50-434e-9ce6-8ff74a01ae07",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.03,
        "y": 0.769
      },
      "kind": "list",
      "text": "Phase 1 Program: Phase 1a dose escalation clinical trial ongoing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d22261a7-e30c-4b67-90d3-0028656ac4e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.95,
        "x": 0.03,
        "y": 0.238
      },
      "kind": "list",
      "text": "Precision Medicine Approach: Discovered at the University of Edinburgh, Scotland; A potent, novel, small molecule inhibitor of YES1/SRC signaling; YES1-Hippo pathway alteration associated with sensitivity to NXP900 in squamous cell models",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef668bc6-dcf8-48c5-a51f-14f08d7b8aae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.43,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "NXP900 Key Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f18f8305-bd0a-4ea4-a110-9188989a14d9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "fa93669e-23c9-4bd8-af74-488eb3bae731",
      "evidence": "list/bullet: Strong Preclinical Proof of Concept: POC in multiple xenograft models – significant single-agent activity in squamous cell cancer models; Ability to re-sensitize resistant NSCLC cells to osimertinib; Ability",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 15,
      "beatId": "8cd99027-3180-4225-abc3-33d73b0fccf4",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Key Highlights and Kinome Profiling for NXP900",
      "position": 5,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 12,
      "name": "Voice Of Customer",
      "slug": "51-voice-of-customer",
      "bestFor": "Product strategy, customer experience, market research",
      "matchId": "d812f16f-0b55-4efb-bb30-cddbdb9254e4",
      "evidence": "NXP800 Potential Opportunity in Multiple Cancers and NXP900 Potential Market Opportunity",
      "position": 1,
      "objective": "Show market potential for NXP800 and NXP900",
      "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response",
      "confidence": 0.6,
      "description": "Let customer quotes and feedback drive the narrative and validate the insight"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}